arrow
S

Scott M. Dehm

University of Minnesota
H指数:49
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Plasma extracellular vesicle proteomics nominates candidate biomarkers of 177Lu-PSMA-617 outcomes in metastatic prostate cancer patients

血浆外泌体蛋白质组学为177Lu-PSMA-617治疗转移性前列腺癌患者的结局提出了候选生物标志物

2026-04-200
OAAI
Convergent evolution of complex structural variants drives therapy resistance in metastatic prostate cancer

复杂结构变异的趋同进化驱动转移性前列腺癌的疗法抗性

2026-04-150
OAAI
Tumor-specific lncRNA IGF1R-AS1 trans-regulates chromatin interactions associated with oncogenic MYC signaling

肿瘤特异性lncRNA IGF1R-AS1跨调控与致癌性MYC信号通路相关的染色质相互作用

2026-03-190
OAAI
Disrupting the interaction between androgen receptor and its coregulator WDR77 delays the growth of treatment-resistant prostate cancer

破坏雄激素受体与其共调节因子WDR77之间的相互作用会延缓治疗抵抗性前列腺癌的生长

2025-09-090
OAAI
Pathogenic Genomic Alterations in Circulating Tumor DNA Predict Overall Survival in Men with Metastatic Castrate-resistant Prostate Cancer

循环肿瘤DNA中的致病基因组改变可预测转移性去势抵抗性前列腺癌患者的总生存期

2025-08-060
PREAI
Reprogramming of Androgen Receptor Activity in Castration-resistant Prostate Cancer is Shaped by Truncated Variants
2025-04-110
OAAI
Adverse prognosis gene expression patterns in metastatic castration-resistant prostate cancer

转移性去势抵抗性前列腺癌的不良预后基因表达模式

2025-02-220
OAAI
Androgen production, uptake, and conversion (APUC) genes define prostate cancer patients with distinct clinical outcomes

雄激素产生,摄取和转化 (APUC) 基因定义了具有不同临床结果的前列腺癌患者

2024-10-221
OA
Final clinical and liquid biopsy (LBx) results of phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI)

二线sacituzumab govitecan(SG)治疗接受过雄激素受体信号抑制剂(ARSI)治疗的转移性去势抵抗性前列腺癌(mCRPC)患者的II期试验的最终临床和液体活检(LBx)结果

2024-09-010
PRE
Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer

同时发生的BRCA2/SPOP突变可预测转移性去势抵抗性前列腺癌中特殊的聚 (ADP-核糖) 聚合酶抑制剂敏感性

2024-08-015
PRE
Integrated analyses highlight interactions between the three-dimensional genome and DNA, RNA and epigenomic alterations in metastatic prostate cancer
2024-07-172
OAAI